Anti-HMGCR antibodies and asymptomatic hyperCKemia. A case report.

Francesca Torri, Greta Ali, Lucia Chico, Gabriele Siciliano, Giulia Ricci

Journal: Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2022;40(2):105-108

PMID: 34355128

Abstract

Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) related myositis is a form of immune-mediated necrotizing myopathy (IMNM). Anti-HMGCR autoantibodies target HMGCR, a glycoprotein linked to the endoplasmic reticulum implied in the cholesterol synthesis pathway, and exert a pathogenic effect on skeletal muscle cells. More than 60% of patients affected by HMGCR-related myositis shares statin-exposure in their medical history. Patients commonly experience CK levels elevation, myalgia, muscle weakness and soreness at variable extent, which manifest acutely or sub acutely with a progressively worsening course, in some cases mimicking limb-girdle muscular dystrophies (LGMD) phenotype and treatment is based on an immunosuppressive strategy. Here we present the peculiar case of a previously statins-exposed 72 y.o. asymptomatic man with persistent moderate hyperCKemia and high levels of anti-HMGCR, in which pharmacotherapy has not been initiated yet, while a wait-and-see approach has been adopted instead.

©2021 Gaetano Conte Academy - Mediterranean Society of Myology, Naples, Italy.

Address: Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.; Department of Surgical Pathology, Medical, Molecular, and Critical Area, University of Pisa, Pisa, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.